Clinical trial shows 39% reduction of ventilator-associated pneumonia with Bactiguard’s endotracheal tube

12 April 2022

A  study has been published on Bactiguard’s endotracheal tube (BIP ETT) that shows a significant reduction of both ventilator-associated pneumonia (VAP) and antibiotic use. This randomized controlled study on 180 intensive care patients was published in the Balcan Medical Journal, in March 2022.

The main objective of the study was to evaluate the efficacy of Bactiguard’s noble-metal alloy coated endotracheal tubes to prevent VAP, compared to standard non-coated endotracheal tubes. The study was conducted in Bukarest, Romania, by Dr Radu Ciprian Tincu and his team.1

Read about the BIP ETT

The study in short

  • Randomized controlled study
  • 180 intensive care patients
  • Comparison between Bactiguard’s infection prevention endotracheal tubes and standard uncoated endotracheal tubes

The results of the study

  • 39% reduction of ventilator associated pneumonia (VAP) per 1000 ventilator days for the group using Bactiguard’s ETTs.
  • Significant reduction in use of antibiotics for patients intubated with Bactiguard’s ETTs.

The conclusion of the study

Bactiguard’s noble metal-alloy coated ETT reduces the incidence of VAP, the number of ventilation days, and leads to a shorter ICU stay for patients in mechanical ventilation.

Read the study

Prevent VAP

Ventilator-associated pneumonia (VAP) is the second most common healthcare-associated infection in intensive care, affecting up to 25% of patients.2–4 Intubation with an endotracheal tube is one important risk factor to develop a VAP, as it increases the risk that bacteria access the lower respiratory tract in different ways.

It is important to prevent VAP since it leads to increased morbidity, mortality, and suffering for the patients. It is also associated with a prolonged hospital stay and higher costs. On average a patient who has developed VAP stays 6.1 additional days in the ICU and 11.5 additional days in the hospital compared to a patient without VAP.5

Bactiguard BIP ETT Evac

About the BIP Endotracheal Tube

BIP ETT is an endotracheal tube with Bactiguard’s unique infection prevention technology. The technology is based on a very thin noble metal alloy coating, firmly attached to the tube surface. When in contact with fluids, the noble metals create a galvanic effect which reduces microbial adhesion. This means that less bacteria adhere to the tube surface, which reduces the risk of biofilm formation leading to infection.

For more information, please contact:
Stefan Grass, Chief Medical Officer and Deputy CEO, mobile +46 70 725 24 48


1. Tincu RD et al. Efficacy of noble metal-alloy endotracheal tubes in ventilator-associated pneumonia prevention: A randomized clinical trial. Balcan Med J. 2022; e-pub ahead of print.
2. Ibrahim EH et al. Chest. 001;120(2):555–561.
3. Craven DE et al. Infect. 1996;11(1):32–53.
4. Rello J et al. Chest. 2002;122(6):2115–2121.
5. Rello J, Ollendorf DA, Oster G, et al.Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 2002;122:2115–21.